Chien-Yu Hsu
Overview
Explore the profile of Chien-Yu Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu Y, Yin Y, Tsai K, Jian C, Liang Z, Hsu C, et al.
J Cell Sci
. 2022 Aug;
135(17).
PMID: 35912788
Epithelial morphogenesis and oncogenic transformation can cause loss of cell adhesion, and detached cells are eliminated by anoikis. Here, we reveal that transforming growth factor β receptor 3 (TGFBR3) acts...
2.
Chen J, Wang H, Su Y, Hsu C, Chen J, Liang C, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638996
A therapeutic approach for promoting neuroprotection and brain functional regeneration after strokes is still lacking. Histone deacetylase 1 (HDAC1), which belongs to the histone deacetylase family, is involved in the...
3.
Chen J, Wang H, Hsu C, Su Y, Chen J, Liang C, et al.
Sci Rep
. 2021 Aug;
11(1):16354.
PMID: 34381129
Stroke is a common cause of death worldwide and leads to disability and cognitive dysfunction. Ischemic stroke and hemorrhagic stroke are major categories of stroke, accounting for 68% and 32%...
4.
Wang H, Chen J, Hsu C, Su Y, Sung T, Liang C, et al.
J Inflamm Res
. 2021 Jun;
14:2363-2376.
PMID: 34103967
Introduction: Cerebral ischemia is a leading cause of disability and death worldwide. However, an effective therapeutic approach for the condition remains undiscovered. The previously proposed growth factor-based therapy has been...
5.
Liu S, Hsu C, Fu R, Huang Y, Chen S, Lin S, et al.
Biomedicine (Taipei)
. 2015 Feb;
5(1):3.
PMID: 25705583
The pluripotent stem cells, including embryonic stem cells (ESCs), are capable of self-renewal and differentiation into any cell type, thus making them the focus of many clinical application studies. However,...
6.
Liu S, Fu R, Wu D, Hsu C, Chang C, Lee W, et al.
Stem Cells Dev
. 2013 Nov;
23(4):421-33.
PMID: 24266622
Induced pluripotent stem (iPS) cells are considered as having the greatest potential for use in cell-based therapies. However, at least two hurdles remain: integrating viral transgenes and introducing the c-Myc...
7.
Liu S, Harn H, Chien Y, Chang C, Hsu C, Fu R, et al.
PLoS One
. 2012 Sep;
7(9):e44024.
PMID: 22970157
In 2006, induced pluripotent stem (iPS) cells were generated from somatic cells by introducing Oct4, Sox2, c-Myc and Klf4. The original process was inefficient; maintaining the pluripotency of embryonic stem...